Processing

Please wait...

Settings

Settings

Goto Application

1. MX2018006026 - UN LIGANTE DE RECEPTOR DE ADENOSINA A3 PARA USO EN EL TRATAMIENTO DE LA ACUMULACION DE GRASA ECTOPICA.

Office
Mexico
Application Number 2018006026
Application Date 15.05.2018
Publication Number 2018006026
Publication Date 28.01.2019
Publication Kind A
IPC
A61K 31/7076
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7042Compounds having saccharide radicals and heterocyclic rings
7052having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
706containing six-membered rings with nitrogen as a ring hetero atom
7064containing condensed or non-condensed pyrimidines
7076containing purines, e.g. adenosine, adenylic acid
CPC
A61K 31/7076
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7042Compounds having saccharide radicals and heterocyclic rings
7052having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
706containing six-membered rings with nitrogen as a ring hetero atom
7064containing condensed or non-condensed pyrimidines
7076containing purines, e.g. adenosine, adenylic acid
A61P 1/16
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1Drugs for disorders of the alimentary tract or the digestive system
16for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61K 9/0053
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
0012Galenical forms characterised by the site of application
0053Mouth and digestive tract, i.e. intraoral and peroral administration
Applicants CAN-FITE BIOPHARMA LTD.
Inventors Pnina FISHMAN
Shira COHEN
Priority Data 242723 23.11.2015 IL
Title
(EN) UN LIGANTE DE RECEPTOR DE ADENOSINA A3 PARA USO EN EL TRATAMIENTO DE LA ACUMULACION DE GRASA ECTOPICA.
(ES) UN LIGANTE DE RECEPTOR DE ADENOSINA A3 PARA USO EN EL TRATAMIENTO DE LA ACUMULACION DE GRASA ECTOPICA.
Abstract
(EN) The present disclosure concerns A3AR ligand for reducing ectopic fat accumulation, particularly in fatty liver. Also provided by the present disclosure is the use of A3AR ligand for the preparation of a pharmaceutical composition for reducing such fat accumulation, method of treating a condition associates with fat accumulation making use of the ligand and kits comprising pharmaceutical compositions comprising the ligand, and instructions for use of same, for treating a condition associated with ectopic fat accumulation. In one embodiment, the present disclosure provides the use of an A3AR agonist, such as 2-Chloro-N6-(3-iodobenzyl)-adenosine-5'-N-methyluron amide (C1-IB-MECA, CF102) for treating fatty liver, specifically, non-alcoholic fatty liver disease (NAFLD).
(ES) La presente descripción se relaciona con ligando de A?AR para reducir acumulación de grasa ectópica, particularmente en hígado graso. También se proporciona por la presente descripción el uso de ligando de A?AR para la preparación de una composición farmacéutica para reducir la acumulación de grasa, método para tratar una condición que se asocia con acumulación de grasa que hace uso del ligando y kit que comprende composiciones farmacéuticas que comprenden el ligando, e instrucciones para uso de las mismas, para tratar una condición asociada con acumulación de grasa ectópica. En una modalidad, la presente descripción proporciona el uso de un agonista de A?AR, como por ejemplo 2-cloro-N6-(3-yodobencil)-adenosin-5'-N-metiluronamida (CI-IB-MECA, CF102) para tratar hígado graso, específicamente, enfermedad de hígado graso no alcohólico (NAFLD).
Related patent documents
RSP-2021/0079This application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.